RhumbLine Advisers
AXSM icon

RhumbLine Advisers’s Axsome Therapeutics AXSM Stock Holding History

RhumbLine Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.72M Sell
51,619
-614
-1% -$106K 0.01% 1124
2025
Q4 		$9.54M Sell
52,233
-8,545
-14% -$1.19M 0.01% 1082
2025
Q3 		$7.38M Sell
60,778
-1,029
-2% -$116K 0.01% 1228
2025
Q2 		$6.45M Buy
61,807
+7,047
+13% +$746K 0.01% 1283
2025
Q1 		$6.39M Buy
54,760
+3,515
+7% +$400K 0.01% 1229
2024
Q4 		$4.34M Sell
51,245
-148
-0.3% -$13.6K ﹤0.01% 1495
2024
Q3 		$4.62M Sell
51,393
-3,538
-6% -$309K ﹤0.01% 1472
2024
Q2 		$4.42M Buy
54,931
+2,674
+5% +$198K ﹤0.01% 1463
2024
Q1 		$4.17M Buy
52,257
+1,620
+3% +$136K ﹤0.01% 1503
2023
Q4 		$4.03M Sell
50,637
-208
-0.4% -$13.9K ﹤0.01% 1550
2023
Q3 		$3.55M Buy
50,845
+4,135
+9% +$309K ﹤0.01% 1536
2023
Q2 		$3.36M Buy
46,710
+2,633
+6% +$194K ﹤0.01% 1619
2023
Q1 		$2.72M Buy
44,077
+1,138
+3% +$74.8K ﹤0.01% 1647
2022
Q4 		$3.31M Buy
42,939
+4,083
+11% +$244K ﹤0.01% 1530
2022
Q3 		$1.73M Buy
38,856
+4,372
+13% +$218K ﹤0.01% 1841
2022
Q2 		$1.32M Buy
34,484
+5,063
+17% +$160K ﹤0.01% 1994
2022
Q1 		$1.22M Sell
29,421
-165
-0.6% -$5.12K ﹤0.01% 2051
2021
Q4 		$1.12M Sell
29,586
-344
-1% -$12.7K ﹤0.01% 2160
2021
Q3 		$986K Buy
29,930
+366
+1% +$14.3K ﹤0.01% 2227
2021
Q2 		$1.99M Sell
29,564
-1,168
-4% -$70.1K ﹤0.01% 1949
2021
Q1 		$1.74M Sell
30,732
-4,968
-14% -$349K ﹤0.01% 1972
2020
Q4 		$2.91M Buy
35,700
+1,041
+3% +$77.8K ﹤0.01% 1656
2020
Q3 		$2.47M Sell
34,659
-9,260
-21% -$722K ﹤0.01% 1557
2020
Q2 		$3.61M Buy
43,919
+5,888
+15% +$453K 0.01% 1393
2020
Q1 		$2.24M Buy
38,031
+3,455
+10% +$282K ﹤0.01% 1488
2019
Q4 		$3.57M Buy
34,576
+2,777
+9% +$112K 0.01% 1462
2019
Q3 		$644K Buy
31,799
+525
+2% +$13.5K ﹤0.01% 2233
2019
Q2 		$805K Buy
+31,274
New +$627K ﹤0.01% 2154
2017
Q2 		– Sell
-13,688
Closed -$53K – 2927
2017
Q1 		$53K Buy
+13,688
New +$65.4K ﹤0.01% 2818

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's AXSM Position: Q1 2026 in Review

RhumbLine Advisers reduced its Axsome Therapeutics (AXSM) stake by 1.2% in Q1 2026, selling an estimated $106K and leaving 51,619 shares worth $8.72M. The position accounts for 0.01% of the portfolio, ranked #1124.

RhumbLine Advisers first reported a position in AXSM in Q1 2017 and has held it in 29 quarters since. The position peaked at $9.54M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • RhumbLine Advisers held 51,619 shares of Axsome Therapeutics worth $8.72M as of Q1 2026.
  • RhumbLine Advisers sold 614 Axsome Therapeutics shares in Q1 2026, an estimated $106K.
  • Axsome Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1124 holding.
  • RhumbLine Advisers first reported a position in Axsome Therapeutics in Q1 2017 and has held it in 29 quarters since.
  • RhumbLine Advisers's Axsome Therapeutics position peaked at $9.54M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.